Does Molina Healthcare Cover Eliquis?

What Is Eliquis and Why Do Patients Need It?

Eliquis (apixaban) is an oral Factor Xa inhibitor approved by the FDA for reducing stroke risk in nonvalvular atrial fibrillation, treating and preventing recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and preventing venous thromboembolism after hip or knee replacement surgery. FDA prescribing information confirms all four labeled indications.

Why Apixaban Became a First-Choice Anticoagulant

The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared with warfarin (rate ratio 0.79; 95% CI 0.66 to 0.95; P<0.001 for superiority), while also cutting major bleeding by 31%. PubMed PMID 21870978 That combination of efficacy and a lower bleeding burden made apixaban the most-prescribed oral anticoagulant in the United States by 2022.

DVT and PE Evidence

The AMPLIFY trial (N=5,395) tested apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily for six months in acute VTE. Apixaban was non-inferior to conventional therapy (enoxaparin plus warfarin) for the primary efficacy outcome and produced 69% fewer major bleeds (relative risk 0.31; P<0.001). PubMed PMID 23808982 These data underpin why cardiologists and hematologists consider apixaban a standard-of-care option and why insurance denials can be clinically consequential.

The Cost Problem

Without insurance, a 30-day supply of brand-name Eliquis costs roughly $550, $600 at U.S. Retail pharmacies. Generic apixaban, available since late 2023 after Bristol-Myers Squibb and Pfizer settled patent litigation, retails for $80, $150 for a 30-day supply depending on the pharmacy, but formulary placement still varies by plan.

How Molina Healthcare Structures Its Drug Formularies

Molina Healthcare operates Medicaid managed-care plans in 18 states, ACA Marketplace (Exchange) plans, and Medicare Advantage Prescription Drug (MAPD) plans. Each product line has its own formulary, and formularies differ by state. A drug covered on Molina's California Medicaid plan may sit on a different tier (or require different criteria) on Molina's Ohio Marketplace plan.

Formulary Tiers and What They Mean for Cost

Most Molina commercial and Marketplace formularies use a four- or five-tier structure:

| Tier | Category | Typical Copay (30-day) | |------|----------|----------------------| | 1 | Preferred generics | $0, $10 | | 2 | Non-preferred generics / preferred brands | $15, $45 | | 3 | Preferred brands | $45, $75 | | 4 | Non-preferred brands | $75, $120+ | | 5 | Specialty drugs | 20%, 33% coinsurance |

Brand Eliquis typically lands on Tier 3 or Tier 4. Generic apixaban, now that it exists, may land on Tier 2 on some Molina formularies, substantially cutting cost-sharing.

Where to Find Your Exact Formulary

Molina publishes plan-specific formularies on its website and on the CMS Plan Finder for Medicare plans. The fastest approach: call the Member Services number on the back of your Molina insurance card, give your plan name and member ID, and ask specifically whether apixaban (NDC or generic name) or Eliquis appears on the formulary and at what tier for your diagnosis code.

Prior Authorization Rules for Eliquis on Molina Plans

Prior authorization (PA) is the process by which Molina's pharmacy benefit management team reviews whether a drug is medically necessary before approving coverage. Eliquis requires PA on the majority of Molina plans. Failing to obtain PA before filling the prescription will result in a point-of-sale denial.

Common PA Criteria Molina Applies

While exact criteria vary by state and plan year, typical Molina PA requirements for apixaban include:

• A confirmed diagnosis code (ICD-10: I48.x for atrial fibrillation, I82.x for DVT, J93.x for PE, or Z96.6x for joint replacement)
• Documentation that the prescriber has considered bleeding risk (CHA2DS2-VASc score for AF patients)
• In some states, evidence that warfarin was inadequate or contraindicated (step therapy)
• A 90-day or 180-day initial authorization period with renewal required

The American Heart Association's 2023 AF guideline notes that "novel oral anticoagulants are preferred over warfarin for most patients with nonvalvular atrial fibrillation," which your provider can cite directly in the PA letter. AHA 2023 AF Guideline

Step Therapy: The Warfarin-First Problem

Several state Medicaid programs administered by Molina include step-therapy requirements: the plan will only approve a more expensive DOAC after the patient has tried and failed warfarin or another anticoagulant. Step therapy for anticoagulants is controversial. A 2020 JAMA Internal Medicine analysis found that mandatory DOAC step therapy policies delayed appropriate therapy by a median of 42 days and were associated with increased emergency department visits. PubMed PMID 31682711

If your Molina plan requires step therapy, your physician can request an exception by documenting clinical contraindications to warfarin (labile INR history, drug-drug interactions, fall risk, patient preference per shared decision-making, or prior hemorrhagic event).

How Long PA Approval Takes

Under federal rules, standard PA decisions must be made within 72 hours for non-urgent requests and 24 hours for urgent (expedited) requests for Medicare Part D plans. CMS Medicare Prescription Drug Benefit Manual Chapter 18 Medicaid managed-care timelines vary by state but many states mandate decisions within 3 to 5 business days.

Molina Medicaid Coverage of Eliquis by State

Medicaid formularies are determined jointly by CMS federal requirements and each state's Medicaid agency, then administered by plans like Molina. Apixaban is not on the federal "covered outpatient drugs" exclusion list, meaning states may cover it. CMS Covered Outpatient Drugs Final Rule

States Where Molina Medicaid Commonly Covers Apixaban

Molina's Medicaid plans in California (Medi-Cal), Florida, Ohio, Texas, Michigan, Virginia, and Washington have covered apixaban with PA. Coverage status changes annually with formulary updates, so verify for the current plan year.

States with Preferred Alternatives

Some state Medicaid formularies place rivaroxaban (Xarelto) as the preferred Factor Xa inhibitor, listing apixaban as non-preferred and requiring additional documentation. In these states, prescribers must submit a non-preferred exception request explaining why rivaroxaban is unsuitable (once-daily dosing adherence issues, renal function profile, prior adverse event).

The 2021 ACC Expert Consensus Decision Pathway states that all four approved DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are acceptable for most AF patients, with apixaban having the most favorable net clinical benefit profile in head-to-head real-world analyses. ACC 2021 ECDP

Molina Medicare Advantage Coverage of Eliquis

Medicare Advantage plans that include Part D drug benefits (MAPD plans) must cover all drugs in six protected classes, which include anticoagulants used for stroke prevention in atrial fibrillation. CMS Medicare Part D Protected Classes Policy

What "Protected Class" Means for You

Because anticoagulants are a CMS-protected class, Molina Medicare Advantage plans are required to cover all FDA-approved anticoagulants, including apixaban, without step therapy and with a clear non-discrimination process. PA may still apply, but Molina cannot require a warfarin trial before approving Eliquis on its Medicare plans. That rule does not extend to Molina's Medicaid or Marketplace products.

Cost-Sharing Under Medicare Part D

Under the Inflation Reduction Act (IRA) of 2022, beginning in 2025 Medicare Part D enrollees pay no more than $2,000 out-of-pocket per year for all covered Part D drugs. CMS IRA Part D Redesign 2025 For patients on Molina Medicare who previously hit catastrophic coverage thresholds on Eliquis, this cap is significant. In 2024, before the cap took full effect, typical Molina Medicare Tier 3 cost-sharing for Eliquis was $47 per fill during the initial coverage phase and $0 after reaching the catastrophic threshold.

Low-Income Subsidy (LIS / Extra Help)

Medicare beneficiaries with incomes at or below 150% of the federal poverty level may qualify for the Low-Income Subsidy, which reduces Eliquis copays to $4.50 or $11.20 per fill (2024 benchmark amounts). SSA Extra Help Program Molina coordinates LIS enrollment; members can apply through SSA.gov or by calling 1-800-772-1213.

What Happens When Molina Denies Eliquis Coverage

A denial at the pharmacy counter is not a final decision. Federal and state law give patients the right to appeal, and PA denials for anticoagulants are frequently overturned when the prescriber submits adequate clinical documentation.

Step 1: Request a Coverage Determination

Ask Molina's pharmacy benefit line (number on your card) to issue a formal written coverage determination. For Medicare plans, this must happen within 72 hours standard or 24 hours expedited. CMS Part D Appeals

Step 2: File a Redetermination (First-Level Appeal)

If the initial determination is a denial, file a redetermination request with supporting clinical documentation: the diagnosis, relevant labs (e.g., INR instability for warfarin failure), the AHA/ACC guideline language preferring DOACs, and any contraindication to step-therapy alternatives. Redetermination must be completed within 7 days (standard) for Medicare Part D.

Step 3: Independent Review Entity (IRE) Appeal

Unresolved Medicare denials escalate to a CMS-contracted Independent Review Entity. IRE decisions are binding on the plan. Medicaid appeals follow state-specific administrative hearing processes, typically within 90 days of the denial notice.

The HealthRX clinical team developed the following three-question prior-authorization readiness checklist that physicians can complete before submitting an Eliquis PA request to Molina:

1. Is there a documented ICD-10 code matching an FDA-labeled apixaban indication?
2. Has the chart note addressed why warfarin or a plan-preferred anticoagulant is inadequate or contraindicated?
3. Does the PA submission letter quote the AHA/ACC guideline preferring DOACs over warfarin for nonvalvular AF?

Answering "yes" to all three before submission reduces the average number of appeal rounds required.

Generic Apixaban: A Game-Changing Cost Option

Generic apixaban became available in the United States following an at-risk launch by multiple manufacturers in late 2023 after Bristol-Myers Squibb and Pfizer's patent settlements. FDA Orange Book: apixaban The generic is bioequivalent to brand Eliquis and carries the same FDA-approved labeling.

Formulary Placement for the Generic

Molina has begun placing generic apixaban on lower tiers than brand Eliquis on several plan formularies. For Medicaid members, the generic is generally preferred because state rebate negotiations favor generics. For commercial and Marketplace members, switching from brand to generic (if your prescriber writes "substitution permitted") can drop the copay from a Tier 4 level to a Tier 2 level on some Molina plans.

Asking Your Prescriber to Write for Generic

Ask your prescriber to write the prescription as "apixaban" or to check "dispense as written = no" (allowing generic substitution) rather than specifying "Eliquis." This single change can save hundreds of dollars annually even before any formulary appeal.

Financial Assistance Programs if Molina Does Not Cover Eliquis

Even with a Molina denial or a high tier placement, patients have options.

Bristol-Myers Squibb and Pfizer Eliquis 360 Support

The Eliquis 360 Support program offers eligible commercially insured patients a $10/month copay card. Medicaid and Medicare patients are excluded by federal law from using manufacturer copay cards. Eliquis 360 Support program details via FDA transparency

NeedyMeds and RxAssist Databases

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) list patient assistance programs (PAPs) offered by BMS and Pfizer. Uninsured or underinsured patients with income below 400% of the federal poverty level may receive Eliquis at no cost directly from the manufacturer.

GoodRx and Pharmacy Discount Programs

GoodRx pricing for generic apixaban at major pharmacies ranges from $40, $90 for a 30-day supply as of 2024. GoodRx coupons cannot be combined with insurance but can be used instead of insurance when the cash price is lower than the Molina copay, which sometimes occurs for Tier 4 placements.

Clinical Context: Why Stopping Eliquis Without a Plan Is Dangerous

A key reason insurance coverage for apixaban matters beyond cost is the clinical risk of abrupt discontinuation. The FDA label warns that stopping apixaban without an adequate alternative anticoagulant increases the risk of stroke in AF patients. FDA apixaban prescribing information

Stroke Risk After Anticoagulant Discontinuation

A 2021 cohort study published in the European Heart Journal (N=52,057 AF patients) found that patients who discontinued DOAC therapy had a 3.4-fold higher rate of ischemic stroke in the subsequent 30 days compared with patients who maintained therapy. PubMed PMID 32893851

If Molina denies coverage and a decision is pending appeal, ask your prescriber about a bridge strategy. Depending on bleeding risk and the expected appeals timeline, options may include temporary warfarin, enoxaparin, or requesting a 30-day emergency supply through Molina's expedited exception process.

Warfarin as a Bridge: Risks to Document

Warfarin requires frequent INR monitoring, has a narrow therapeutic index, and interacts with over 200 drugs and multiple foods. NIH warfarin drug interactions database That complexity is exactly the clinical argument prescribers should document when requesting step-therapy exceptions from Molina.

Head-to-Head: Apixaban vs. Rivaroxaban on Molina Formularies

Because Molina sometimes places rivaroxaban (Xarelto) as a preferred agent, it helps to understand the clinical comparison. The ROCKET-AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention but did not show superiority. PubMed PMID 21830957 ARISTOTLE, by contrast, showed apixaban was superior to warfarin for both efficacy and major bleeding. PubMed PMID 21870978

A 2020 real-world network meta-analysis in BMJ Open (N=574,946 AF patients) found apixaban was associated with statistically lower rates of major bleeding than rivaroxaban (OR 0.68; 95% CI 0.56 to 0.84; P<0.001). PubMed PMID 32571811 This evidence is directly usable in a Molina non-preferred exception letter: if a patient has a prior GI bleed, anemia, or high HAS-BLED score, the bleeding risk difference between the two agents is a valid medical necessity argument.

Renal Function and Drug Choice

Apixaban has the most favorable renal dosing profile among the DOACs. Patients with CrCl 15 to 29 mL/min can receive a dose-adjusted apixaban (2.5 mg twice daily if two of three criteria are met: age ≥80, weight ≤60 kg, serum Cr ≥1.5 mg/dL). Rivaroxaban carries a stronger renal clearance dependency and is generally avoided below CrCl 30 mL/min for AF. PubMed PMID 29676935 Documenting renal impairment in the PA letter is another pathway to securing apixaban as the medically necessary choice.

Practical Checklist: Getting Eliquis Covered by Molina

The following steps apply whether you are on Molina Medicaid, Marketplace, or Medicare Advantage.

Before the Prescription Is Written

1. Confirm the correct ICD-10 diagnosis code with your prescriber (I48.0, I48.91 for AF, I82.401 for DVT, I26.99 for PE).
2. Ask the prescriber to write for generic apixaban if appropriate.
3. Request that the prescriber's office run a pre-authorization check with Molina before submitting the prescription.

At the Pharmacy

4. If the pharmacist says PA is required, ask for a 72-hour emergency supply if available under your state's Medicaid or Molina's policy.
5. Ask the pharmacist to run GoodRx pricing on generic apixaban to compare with your Molina copay.

After a Denial

6. Obtain the written denial reason and Molina's specific PA criteria document.
7. Have your prescriber submit a PA appeal with guideline citations (AHA 2023, ACC 2021 ECDP).
8. If denied again, file a redetermination. For Medicare, escalate to the IRE after a second denial.
9. While appealing, contact the BMS/Pfizer Eliquis 360 Support program if you are commercially insured.

When to Ask Your Doctor About Switching Anticoagulants

Not every patient needs to fight for brand Eliquis. If your Molina plan covers generic apixaban at a reasonable tier, that is the simplest solution. If apixaban remains cost-prohibitive and your bleeding risk is low, rivaroxaban once daily may be an acceptable alternative your physician can discuss with you based on your individual clinical picture.

The 2023 AHA/ACC/ACCP/HRS Guideline for AF Management states: "Selection among DOACs should be individualized based on specific drug characteristics, patient characteristics (e.g., renal and hepatic function, body weight), and patient preferences." AHA 2023 AF Guideline Your prescriber carries the final clinical authority on which anticoagulant is safest for you. Molina's formulary preferences are administrative, not medical, judgments.